A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing …

RW Sanders, R Derking, A Cupo, JP Julien… - PLoS …, 2013 - journals.plos.org
A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-
1) vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One …

CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants

H Dreja, C Pade, L Chen… - Journal of General …, 2015 - microbiologyresearch.org
All human immunodeficiency virus type-1 (HIV-1) viruses use CD4 to enter cells.
Consequently, the viral envelope CD4-binding site (CD4bs) is relatively conserved, making …

Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects

DN Sather, L Stamatatos - Vaccine, 2010 - Elsevier
The characterization of the cross-reactive, or heterologous, neutralizing antibody (NAb)
responses developed during HIV-1-infection is relevant to the development of an HIV …

Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells

NL Board, Z Yuan, F Wu, M Moskovljevic, M Ravi… - Nature …, 2024 - nature.com
The persistence of CD4+ T cells carrying latent human immunodeficiency virus-1 (HIV-1)
proviruses is the main barrier to a cure. New therapeutics to enhance HIV-1-specific immune …

[PDF][PDF] Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir

JK Rajashekar, J Richard, J Beloor, J Prévost… - Cell host & …, 2021 - cell.com
Small CD4-mimetic compounds (CD4mc) sensitize HIV-1-infected cells to antibody-
dependent cellular cytotoxicity (ADCC) by facilitating antibody recognition of epitopes that …

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

PL Moore, ES Gray, D Sheward, M Madiga… - Journal of …, 2011 - Am Soc Microbiol
The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV
vaccine field. We have identified a subtype C HIV-1-superinfected individual, CAP256, with …

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

ES Gray, N Taylor, D Wycuff, PL Moore… - Journal of …, 2009 - Am Soc Microbiol
Defining the specificities of the anti-human immunodeficiency virus type 1 (HIV-1) envelope
antibodies able to mediate broad heterologous neutralization will assist in identifying targets …

The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody

SS Balla-Jhagjhoorsingh, D Corti, L Heyndrickx… - PloS one, 2013 - journals.plos.org
Immunogen design for HIV-1 vaccines could be based on epitope identification of naturally
occurring neutralizing antibodies in infected patients. A tier 2 neutralizing monoclonal …

Passive immunization as tool to identify protective HIV-1 Env epitopes

VG Kramer, NB Siddappa, RM Ruprecht - Current HIV research, 2007 - ingentaconnect.com
The HIV-1/AIDS epidemic continues to escalate, and a protective vaccine remains elusive.
The first vaccine candidate, gp120, did not induce broadly neutralizing antibodies (nAbs) …

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

DH Barouch, JB Whitney, B Moldt, F Klein, TY Oliveira… - Nature, 2013 - nature.com
Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with
extraordinary potency and breadth have recently been described. In humanized mice …